Advanced Medical Solutions ends year in line with expectations

Tissue healing technology developer Advanced Medical Solutions (AMS) said in a trading update on Wednesday that its full-year results for 2023 were expected to fall within its previously published guidance ranges.

Advanced Medical Solutions Group
03 May 2024 17:20:37

Source: Sharecast

The AIM-traded firm said revenue was projected to be in the range of £124m to £127m, and adjusted profit before tax was anticipated to be between £25m and £27m.

Its positive outlook for 2024 was meanwhile underpinned by the successful execution of strategic marketing initiatives and product launches throughout 2023.

Key highlights included the revitalisation of its US LiquiBand distribution strategy, marked by the completion of all three US hospital distribution agreements since October.

The new approach contributed to increased order intake and growth in both the $200m small-wound market and the emerging $70m long-wound market.

AMS said the pipeline of evaluations and conversions for LiquiBand XL was also rapidly expanding, bolstering confidence in achieving record US LiquiBand revenues in 2024.

Additionally, AMS said it was making strides in the US launch of LiquiBandFix8 and LiquiFix.

The company said its new commercial partner TELA Bio had conducted extensive training among its specialist hernia salesforce.

Promising progress was being made across several significant group purchasing organisation (GPO) systems in the US, with a full in-market launch expected late in the first quarter.

“I am delighted with the strategic progress we have made across the group in 2023, creating significant new opportunities for AMS,” said chief executive officer Chris Meredith.

“The completion of the new US LiquiBand route to market strategy, the US Connexicon acquisition and the roll-out of LiquiBand XL will support the delivery of record US LiquiBand revenues in 2024 and sets us up strongly to deliver our target of doubling our market share over the next five years.

“With the US launch of LiquiFix progressing well and continued growth being generated from more established brands such as Resorba and ActivHeal, we are confident that the group will generate strong and sustainable growth in 2024 and in the long term.”

At 1200 GMT, shares in Advanced Medical Solutions were up 5.63% at 214.43p.

Reporting by Josh White for Sharecast.com.

Transferring your account

Transfer your existing ISAs and Share Dealing Accounts and you could save money. In order to transfer, log in to your existing account and complete the online application form. We’ll do the rest for you. It’s free to transfer (we will not charge you). Please check your current provider to see if they have any charges for transferring.

Transfer to us

N/A

Isin: N/A

Exchange: N/A

Sell:

N/A

Buy:

N/A

Change:

Date:

Prices delayed by at least 15 minutes

Compare our accounts

Whether you're looking for a Share Dealing Account, Stocks and Shares ISA or a Self-Invested Personal Pension (SIPP), we've got an account to suit your needs.

View our accounts

Bank of Scotland is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.

Important legal information

Bank of Scotland Share Dealing Service is operated by Halifax Share Dealing Limited. Halifax Share Dealing Limited. Registered in England and Wales No. 3195646. Registered Office: Trinity Road, Halifax, West Yorkshire HX1 2RG. Authorised and regulated by the Financial Conduct Authority, 12 Endeavour Square, London, E20 1JN under number 183332. A Member of the London Stock Exchange and an HM Revenue & Customs Approved ISA Manager.

The information contained within this website is provided by Allfunds Digital, S.L.U. acting through its business division Digital Look Ltd unless otherwise stated. The information is not intended to be advice or a recommendation to buy, sell or hold any of the shares, companies or investment vehicles mentioned, nor is it information meant to be a research recommendation. This is a solution powered by Allfunds Digital, S.L.U. acting through its business division Digital Look Ltd incorporating their prices, data news, charts, fundamentals and investor tools on this site. Terms and conditions apply. Prices and trades are provided by Allfunds Digital, S.L.U. acting through its business division Digital Look Ltd and are delayed by at least 15 minutes.

Data provided by FE fundinfo. Care has been taken to ensure that the information is correct, but FE fundinfo neither warrants, represents nor guarantees the contents of information, nor does it accept any responsibility for errors, inaccuracies, omissions or any inconsistencies herein. Past performance does not predict future performance, it should not be the main or sole reason for making an investment decision. The value of investments and any income from them can fall as well as rise.